Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial - Williams, B; MacDonald, T M; Morant, S (Lancet, 2015)
et al.